AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10 avr. 2024 08h21 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08 avr. 2024 16h05 HE
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
01 avr. 2024 07h00 HE
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28 mars 2024 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...
Global Generic Oncology Sterile Injectable Market Set for Rapid Growth, Forecast 2024: New Research Report
22 mars 2024 10h38 HE
|
Research and Markets
Dublin, March 22, 2024 (GLOBE NEWSWIRE) -- The "Generic Oncology Sterile Injectable Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global generic...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
22 mars 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Theratechnologies entreprend l’augmentation de la dose dans l’essai clinique de phase I sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
21 mars 2024 07h30 HE
|
Theratechnologies
Le comité d’examen médical a approuvé la mise en place du recrutement de la prochaine cohorte de patientes, conformément au protocole d’optimisation des dosesUne première patiente du groupe qui en...
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21 mars 2024 07h30 HE
|
Theratechnologies
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
20 mars 2024 09h25 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
15 mars 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...